Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Varegacestat Reference Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Reference Formulation, then Test Formulation | EXPERIMENTAL | - |
| Test Formulation, then Reference Formulation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Varegacestat Reference Formulation | DRUG | Oral administration |
| Varegacestat Test Formulation | DRUG | Oral administration |
Inclusion Criteria: * Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit * Male participants must follow protocol-specified contraception guidance * Continuous non-smoker who has not used nicotine and tobacco containing products fo...
Varegacestat Reference Formulation is an investigational small molecule being studied in healthy volunteers. It is being evaluated in Phase 1 clinical trials to examine its effects, including how it interacts with other drugs, how the body processes it, and its bioavailability. It is not approved for any disease and remains in clinical development.
Varegacestat Reference Formulation is being developed by Immunome, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IMNM. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy participants in the United States.
Varegacestat Reference Formulation is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Four Phase 1 trials have been conducted or initiated, with one currently recruiting participants and the others completed.
Varegacestat Reference Formulation has been studied in four Phase 1 trials. These include NCT06677996, examining effects of itraconazole after single dose administration; NCT06841315, a hepatic impairment study; NCT06845852, a mass balance study; and NCT07610005, a relative bioavailability and bioequivalence study, which is currently recruiting.
Varegacestat Reference Formulation belongs to the -stat class of enzyme inhibitors, indicating it targets an enzyme. The specific molecular target is not disclosed in the available clinical trial information. It is being studied in healthy volunteers to assess its pharmacokinetic properties and safety.
Yes, Varegacestat is also known as AL102. In clinical trial NCT06677996, the study title refers to Varegacestat (AL102), confirming these names refer to the same investigational drug. This alternative name may appear in scientific literature and other trial registrations.